We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Company expects strong organic growth in sales, EBITDA in 2022
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
